ASCO 2018: Immunotherapy in Prostate Cancer: The Path Forward – UroToday
Tech Times |
ASCO 2018: Immunotherapy in Prostate Cancer: The Path Forward
UroToday Such studies assessed the effect of addition of other accepted treatments such as enzalutamide, PARP inhibitors, Radium 223, and docetaxel, to immunotherapy. Docetaxel in fact, induces immunogenic modulations, and causes increased expression of … Immunotherapy Drug Keytruda Halts 'Untreatable' Prostate Cancer In Some Men Prostate cancer drug Keytruda shows positive results in a few men during first clinical trial Immunotherapy could stop prostate cancer spreading, trial shows |
